Successful use of recombinant factor VIIa (NovoSeven) during cardiac surgery in a pediatric patient with congenital factor XI deficiency.

Abstract

We report our experience with the use of recombinant activated factor VII (rFVIIa) during cardiac surgery in a 4.5-year-old boy with severe congenital FXI deficiency and a congenital heart disease. After weaning the patient from cardiopulmonary bypass, the first intravenous dose of rFVIIa (90 microg/kg) was administered. This same dosage was repeated eight more times, at 2- to 4-hour intervals postoperatively. There was no bleeding during and after surgery. rFVIIa treatment may be used successfully in children with severe FXI deficiency in major operations such as open heart surgery.

• Authors: Zekai Avci, Baris Malbora, Mahmut Gokdemir, Suleyman Ozkan, Namik Ozbek
• Journal: Pediatric cardiology (Pediatr Cardiol) Vol. 29 Issue 1 Pg. 220-2 (Jan 2008) ISSN: 0172-0643 [Print] United States
• PMID: 17885783 (Publication Type: Case Reports, Journal Article)

Chemical References

• Recombinant Proteins
• recombinant FVIIa
• Factor VIIa

Topics

• Abnormalities, Multiple (surgery)
• Cardiopulmonary Bypass
• Child, Preschool
• Factor VIIa (administration & dosage, therapeutic use)
• Factor XI Deficiency (congenital, drug therapy)
• Heart Defects, Congenital (surgery)
• Humans
• Male
• Mitral Valve (surgery)
• Recombinant Proteins (administration & dosage, therapeutic use)